Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

NCT02847468 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

61

Enrollment

OTHER

Sponsor class

Stopped Insufficient recruitment

Conditions

Carcinoma, Hepatocellular

Interventions

OTHER: FDG Positron Emission Tomography
OTHER: FCH Positron Emission Tomography

Sponsor

Centre Georges Francois Leclerc